We founded Synthena to study one substance, PDRN
Synthena makes PDRN without animal-derived sources and aims at a fragment-length range of 20 to 80 base pairs.
Most PDRN in use comes from animal tissue, in fragments of many lengths. We wanted to know what changes when the source is plant or microbial and the fragments are held to a defined range. We founded Synthena Pharmaceuticals in July 2026 to carry that work forward.
PDRN is a mixture of short DNA fragments, and it is the only substance we work on. With one substance there is no second molecule to turn to when the first is difficult.
The material
We answer our question by measuring the same material batch after batch and keeping every result with its history. When a result surprises us, we repeat it.
Where the work stands
We study this one material in five fields of human biology, from the circulation to the nervous system. We state the stage each programme has reached. What we learn in one field holds in the others, because the material is the same.
Our founder presented this research at the Royal Society on 7 November 2025, before the company was formed.
Marshon
About Synthena Pharmaceuticals
Synthena Pharmaceuticals is a pharmaceutical company founded in Hong Kong in July 2026 and focused on one substance, PDRN. Its aim is to turn PDRN into medicines made without animal-derived sources, produced within a defined fragment-length range and studied across five fields of human biology. Its most advanced programme is preclinical; no Synthena medicine has entered clinical trials or been approved for any indication.
This page describes research and development. It does not establish the safety or efficacy of any Synthena medicine.
